Product Information
Registration Status: ActiveRENVELA TABLET 800MG is approved to be sold in Singapore with effective from 2009-06-11. It is marketed by SANOFI-AVENTIS SINGAPORE PTE LTD, with the registration number of SIN13725P.
This product contains Sevelamer 800mg in the form of TABLET, FILM-COATED. It is approved for ORAL use.
This product is manufactured by Genzyme Ireland LTD in IRELAND.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Description
Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. When taken with meals, sevelamer binds to dietary phosphate and prevents its absorption. It is marketed by Genzyme under the trade name Renagel.
Indication
For the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on hemodialysis.
Mechanism of Action
Sevelamer prevents hyperphosphatemia by binding to dietary phosphate in the gut, preventing its absorption and thus decreasing serum parathyroid hormone levels.
Pharmacokinetics
- Absorption
- Not absorbed following oral administration, however no absorption studies have been performed in patients with renal disease.
- Distribution
- Metabolism
- Elimination
Toxicity
Sevelamer has been given to normal healthy volunteers in doses of up to 14 grams per day for eight days with no adverse effects. Sevelamer has been given in average doses up to 13 grams per day to hemodialysis patients. There are no reported overdosages of sevelamer in patients. Since sevelamer is not absorbed, the risk of systemic toxicity is low.
Active Ingredient/Synonyms
Sevelamer | Sévélamer | Sevelamero | Sevelamerum | Sevelamer |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.